Shanghai Helioson Pharmaceutical Co., Ltd.
1 clinical trials · Sponsor
◉ Watch Shanghai Helioson Pharmaceutical Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT07658352) | Shanghai Helioson Pharmaceutical Co., Ltd. | 2026-06-26 |
Track Shanghai Helioson Pharmaceutical Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.